374 studies found for:    Open Studies | Exclude Unknown | "heart disease"OR"stroke"OR"cardiovascular disease" | United States | Phase 1, 2, 3, 0 | Industry
Show Display Options
Rank Status Study
21 Recruiting SPYRAL HTN-ON MED Study
Conditions: Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
22 Recruiting SPYRAL HTN-OFF MED Study
Conditions: Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
23 Recruiting The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above the Knee
Conditions: Peripheral Arterial Disease;   Cardiovascular Disease;   Peripheral Vascular Disease
Intervention: Other: Paclitaxel administration using the OPC
24 Recruiting BIONICS - Pharmacokinetics (PK) Trial
Condition: Heart Disease
Intervention: Device: BioNIR Ridaforolimus Eluting Coronary Stent
25 Recruiting A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS)
Condition: Brain Ischemia
Interventions: Drug: alteplase [Activase];   Drug: alteplase placebo;   Drug: aspirin;   Drug: aspirin placebo
26 Recruiting Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
Condition: Congenital Heart Disease
Intervention: Drug: sulphur hexafluoride lipid-type A microspheres
27 Recruiting Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Condition: Thrombosis
Interventions: Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
28 Recruiting Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery
Conditions: Anemia;   Cardiovascular Disease
Interventions: Drug: EPO;   Drug: Feraheme
29 Recruiting Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Interventions: Drug: Eleclazine;   Drug: Placebo
30 Recruiting A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System
Conditions: Congestive Heart Failure;   Left Ventricular (LV) Systolic Dysfunction
Intervention: Device: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
31 Recruiting Bococizumab HIV Evaluation (B-HIVE) Study
Conditions: Dyslipidemia;   Cardiovascular Disease
Interventions: Drug: Bococizumab;   Drug: Placebo
32 Recruiting BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Conditions: Pediatrics;   Muscle Spasticity;   Cerebral Palsy;   Stroke
Intervention: Biological: botulinum toxin Type A
33 Recruiting BOTOX® Treatment in Pediatric Upper Limb Spasticity
Conditions: Pediatrics;   Muscle Spasticity;   Cerebral Palsy;   Stroke
Interventions: Biological: botulinum toxin Type A;   Drug: Normal Saline (Placebo)
34 Recruiting Treadmill CV Safety Study
Condition: Stable Angina
Interventions: Drug: AMG 334;   Drug: Placebo
35 Recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
36 Recruiting Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study
Condition: Chronic Aphasia
Interventions: Device: HD-tDCS (Soterix Medical, Active);   Device: HD-tDCS (Soterix Medical, Sham)
37 Recruiting Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Condition: Prevention &Amp; Control
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
38 Recruiting Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women
Condition: Cardiovascular Disease
Interventions: Dietary Supplement: ResA;   Dietary Supplement: Resveratrol;   Dietary Supplement: Placebo
39 Recruiting Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
Condition: Acute Coronary Syndrome
Interventions: Drug: dalcetrapib;   Drug: Placebo
40 Recruiting Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Condition: Myocardial Infarction
Intervention: Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years